Table 4 Baseline characteristics in treatment
Untreated | Anti-fibrotic treatment | P-value* | ||||
|---|---|---|---|---|---|---|
All | Pirfenidone | Nintedanib | Switched | |||
N | 150 | 330 | 166 | 142 | 22 | |
Age, years, at enrolment into the registry | 74.5 (70.0–79.0) | 73.0 (67.0–77.0) | 73.0 (68.0–78.0) | 73.0 (67.0–78.0) | 69.5 (64.0–73.0) | 0.018 |
Age, years, at diagnosis | 73.0 (69.0–78.0) | 72.0 (66.0–77.0) | 72.0 (67.0–77.0) | 72.0 (66.0–77.0) | 67.0 (63.0–70.0) | 0.027 |
Gender (male, n, %) | 100 (66.7) | 242 (73.3) | 128 (77.1) | 98 (69.0) | 16 (72.7) | 0.135 |
Smoking history (yes, n, %) | 99 (66.0) | 218 (66.1) | 118 (71.1) | 88 (62.0) | 12 (54.5) | 0.99 |
BMI | 26.2 (23.6–29.1) | 27.1 (24.5–30.0) | 26.9 (24.5–29.9) | 27.2 (24.5–30.0) | 27.9 (24.7–30.1) | 0.052 |
FVC, % predicted | 72.0 (62.0–86.0) | 69.0 (60.0–82.0) | 69.0 (60.0–80.0) | 72.0 (60.5–85.0) | 65.0 (61.0–77.0) | 0.169 |
DLCO, % predicted | 50.0 (42.0–59.5) | 47.0 (37.0–56.0) | 46.0 (36.0–56.0) | 47.0 (37.0–56.0) | 47.0 (41.0–56.0) | 0.044 |
TLC, % predicted | 66.0 (58.5–73.0) | 65.0 (55.0–72.0) | 64.0 (55.0–71.0) | 65.0 (56.0–73.0) | 66.0 (56.0–71.0) | 0.072 |
CPI | 44.1 (38.1–51.3) | 48.9 (41.4–55.7) | 49.7 (41.4–56.5) | 48.9 (41.7–55.3) | 46.2 (37.4–55.4) | 0.002 |
GAP stage | 2 (1–2) | 2 (1–2) | 2 (1–2) | 2 (1–2) | 1 (1–2) | 0.426 |
6MWD (m) | 418 (360–477) | 430 (365–503) | 420 (351–495) | 435 (385–498) | 473 (393–536) | 0.211 |